Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.50 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29882808 | 1.00 | OPRD1 (0.50) | OPRD1OPRM1MMESLC6A2CTSC | |
| SCHEMBL30746746 | 0.98 | OPRD1 (0.49) | OPRD1OPRM1MMESLC6A2CTSC | |
| SCHEMBL31453800 | 0.92 | OPRM1 (0.40) | OPRD1OPRM1MMESLC6A2ECE1 | |
| SCHEMBL30254475 | 0.90 | OPRM1 (0.39) | OPRD1OPRM1MMESLC6A2ECE1 | |
| SCHEMBL31063872 | 0.90 | OPRD1 (0.44) | OPRD1OPRM1OPRK1BACE1 | |
| SCHEMBL30799513 | 0.89 | BACE1 (0.49) | OPRD1OPRM1MMEBACE1 | |
| SCHEMBL30009160 | 0.88 | CALCRL (0.48) | OPRD1OPRM1OPRK1BACE1 | |
| SCHEMBL31039959 | 0.88 | MME (0.45) | OPRD1OPRM1MMESLC6A2 | |
| SCHEMBL31259942 | 0.88 | MME (0.47) | MMEGNPAT | |
| SCHEMBL30578424 | 0.88 | MME (0.47) | MMEGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624063-B2 | Compositions and methods for modification of target molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260109753-A1 | Syntac Polypeptides and Uses Thereof | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2026-04-23 | — | — | US | disclosed |
| US-12595314-B2 | Antibody specific for GPC3 and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12590321-B2 | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | EXUMA BIOTECH CORP. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12583930-B2 | Human glucose-dependent insulinotropic polypeptide receptor (GIPR) antibodies and methods of use thereof to inhibit GIP receptor and signaling | CRYSTAL BIOSCIENCE INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260049116-A1 | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260015381-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | UNIV CALIFORNIA (US) | 2026-01-15 | — | — | US | disclosed |
| EP-3589733-B1 | METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF | EXUMA BIOTECH CORP (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4650365-A2 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250304698-A1 | PROTEOLYTICALLY CLEAVABLE CHIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-10-02 | — | — | US | disclosed |
| US-20220119549-A1 | SHIELDED BIOLOGICS WITH MASKING DOMAINS TO SHIELD ANTIGEN BINDING CAPABILITY OF BIOLOGICS AND USES THEREOF | Tavotek Biotherapeutics (Hong Kong) Limited | 2022-04-21 | — | — | US | disclosed |
| US-20220119483-A1 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2022081794-A1 | SHIELDED BIOLOGICS WITH MASKING DOMAINS TO SHIELD ANTIGEN BINDING CAPABILITY OF BIOLOGICS AND USES THEREOF | Tavotek Biotherapeutics (Hong Kong) Limited (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-20220112252-A1 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. | 2022-04-14 | — | — | US | disclosed |
| CN-114340671-A | Antibodies specific for GPC3 and methods of use thereof | R.P.谢勒技术有限责任公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220106378-A1 | T-CELL MODULATORY ANTIGEN-PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3976084-A1 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220089680-A1 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220089681-A1 | METHODS FOR MODULATING AN IMMUNE RESPONSE | CUE BIOPHARMA, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220079985-A1 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595314-B2 | Antibody specific for GPC3 and methods of use thereof | IGLV6-57, IGSF11, VSIG8 | OPRD1 3024/4885OPRM1 4141/4885MME 3416/4885 |
| US-20260109753-A1 | Syntac Polypeptides and Uses Thereof | ICOS, CD40LG, CD40 | OPRD1 754/4885OPRM1 516/4885MME 1681/4885 |
| US-12624063-B2 | Compositions and methods for modification of target molecules | TYR, TH, COMT | OPRD1 1825/4885OPRM1 663/4885MME 1589/4885 |
| US-20260049116-A1 | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | IL2, IL2RA, MICA | OPRD1 1034/4885OPRM1 1845/4885MME 2063/4885 |
| US-20260015381-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | TH, COMT, TYR | OPRD1 516/4885OPRM1 132/4885MME 1749/4885 |
| US-12583930-B2 | Human glucose-dependent insulinotropic polypeptide receptor (GIPR) antibodies and methods of use thereof to inhibit GIP receptor and signaling | GIPR, GLP1R, GPR119 | OPRD1 432/4885OPRM1 688/4885MME 3512/4885 |
| US-12590321-B2 | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | CD4, PBK, CD69 | OPRD1 2980/4885OPRM1 2801/4885MME 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.